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The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a potent inducer of tumor cell apoptosis, but concerns
of considerable liver toxicity limit its uses in human cancer therapy. Here, we show that i.v. injected Escherichia coli DH5a (E. coli
DH5a) specifically replicates in solid tumors and metastases in live animals. E. coli DH5a does not enter tumor cells and suits for
being the vector for soluble TRAIL (sTRAIL), which induces apoptosis by activating cell-surface death receptors. With the high
‘tumor-targeting’ nature, we demonstrate that intratumoral (i.t.) and intravenous injection of sTRAIL-expressing E. coli DH5a results
in the tumor-targeted release of biologically active molecules, which leads to a dramatic reduction in the tumor growth rate and the
prolonged survival of tumor-bearing mice. TRAIL delivery by E. coli DH5a did not cause any detectable toxicity to any organs,
suggesting that E. coli DH5a-delivered sTRAIL protein therapy may provide a feasible and effective form of treatment for solid
tumors.
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Introduction
The tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) is a type-II transmembrane
protein that was initially identified based on homology of
the extracellular domain to CD95L, TNF and LTa.
1,2
The membrane-bound and the soluble extracellular
domains of TRAIL (amino acids 95–281 or 114–281)
induce apoptosis in a wide variety of tumor cell lines.
Approximately two-thirds of tumor cell lines tested are
sensitive to the cytotoxic effects of TRAIL in vitro,
3,4
suggesting that TRAIL may be exploited as a powerful
antitumor agent. Repeated intravenous administration of
recombinant, biologically active TRAIL (rTRAIL) can
induce tumor cells apoptosis, suppress tumor progression
and improve survival in tumor-bearing mice.
5,6 Unfortu-
nately, the use of TRAIL as a therapeutic agent is limited
by severe cytotoxicity in normal hepatocytes,
7,8 esopha-
geal epithelial cells,
9 prostate epithelial cells
10 and
keratinocytes
11 in vitro, and its short half-life after
systemic administration in vivo.
12
Gene therapy may enable continuous production of
TRAIL in substantial amounts for a relatively long period
of time. This strategy would overcome the necessity for
repeated injections of recombinant TRAIL and may also
result in increased antitumor effect. The transfer and
expression of TRAIL into cells by adenovirus or adeno-
associated virus induces apoptosis and apoptotic
bystander effects in several human cancer cells in vitro
and in xenograft models of human tumors.
13–15 However,
adenovirus or adeno-associated virus-based vectors may
cause hepatotoxicity through innate and cell-mediated
immune responses, and have less targeting to the tumor
site when systemically administrated.
16,17
It has been known for more than 60 years that
anaerobic bacteria can selectively grow in tumors.
18–21
Several approaches to developing anaerobic bacteria for
tumor therapies have been described. The anaerobic
species Bifidobacterium longum
22,23 and Clostridum
novyi
24,25 could selectively grow in the hypoxic environ-
ment of large solid tumors. Recently, Salmonella typhi-
murium with attenuated lipid-A was evaluated in a phase-
I clinical trial.
26,27 To overcome toxicity, Zhao et al.
28–30
mutagenized S. typhimurim and selected an amino-acid
auxotrophic strain, which selectively grew in and killed
tumor cells. Non-pathogenic Escherichia coli is a faculta-
tive anaerobic bacterium that naturally resides in the
digestive tracts of humans and other animals. There have
been no reports to date describing the use of E. coli as an
anticancer protein-delivery agent to repress tumor growth
in vivo.
31,32
Minimizing side effects while maximizing tumor
targeting is the greatest challenge of current tumor
therapeutic protocols. Here, we show that intravenously
(i.v.) injected E. coli specifically replicates in solid tumors
and metastases in live animals. With this high ‘tumor-
targeting’ nature, we describe a novel treatment of
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www.nature.com/cgtinjecting TRAIL-expressing E. coli so that it can grow
loco-regionally inside tumors and release the biologically
active soluble TRAIL (sTRAIL) protein at relatively high
levels, thereby achieving maximal therapeutic effects while
sparing potential systemic side effects.
Materials and methods
Cell lines and cell culture
Murine B16-F10-luc
þ melanoma cells and human NCI-
H460 lung tumor cells were obtained from Xenogen
(Hopkinton, MA, USA) and ATCC (Rockville, MD,
USA), respectively. B16-luc
þ were grown in Dulbecco’s
modified Eagle’s medium (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum, 1%
non-essential amino acids, L-glutamine, and sodium
pyruvate (all from Hyclone, Ogden, UT, USA); MEM
vitamin solution (Invitrogen); and 1% penicillin and
streptomycin. NCI-H460 cells were grown in RPMI-1640
medium supplemented with 10% fetal bovine serum, and
1% penicillin and streptomycin. All the cells were cultured
at 371C in a humidified atmosphere of 5% CO2. H460
cells were transfected with pcDNA3.1-Luc
þ vector
containing firefly luciferase using Lipofectamine 2000
(Invitrogen). Stable clones expressing luc were isolated in
the presence of 300mgml
 1 geneticin (G418) and the clone
with the highest level of luc expression (as determined by
bioluminescence) was selected by using D-luciferin and an
In Vivo Imaging System (IVIS) (Xenogen).
Bacterial strains and plasmids
E. coli DH5a were routinely grown in LB medium and
cultured in a shaker at 371C. The plasmid pMK
luxABCDE, also called pXen-1 (Xenogen), which con-
tains bacterial luciferase, was electroporated into DH5a
and positive transformants were screened with an
IVIS.
33,34 The clone with the highest bioluminescence
was grown overnight at 371C in LB medium containing
100mgml
 1 ampicillin. The bioluminescent clones were
stored at  801C and thawed before use. Bacterial
concentration was estimated spectrophotometrically by
determining absorbance at 600nm, and cell numbers were
verified by plating dilutions of inoculum onto LB agar
plate (1 ODE8(10
8c.f.u.ml
 1).
A sense primer (50-GCGGATCCGACCTCTGAGGA
AACCATTTC-30) and antisense primer (50-CCGCTC
GAGTTAGCCAACTAAAAAGGCCC-30) were used to
amplify a 561-bp DNA fragment representing the sTRAIL
from mammary library by PCR. The products were gel-
purified, digested with BamHI and XhoI restriction enzymes,
repurified and inserted into the BamHI and XhoIs i t e so f
the prokaryotic expression vector pGEX-KG (Amersham
Biosciences, Piscataway, NJ). The resulting vector pGEX-
sTRAIL was electroporated into E. coli DH5a and the
resulting clone was termed as E. coli DH5a (sTRAIL).
Protein expression was induced by 0.1mM isopropyl-b-
thiogalacto pyranoside in culture and protein production
was analyzed by Coomassie brillant blue (CBB) staining.
Recipient animals and tumor models
Female BALB/c and nude mice were housed under aseptic
conditions in micro-isolator cages. The animals used in
the studies were approximately 4–6 weeks of age and
weight ranged between 20±5 and 18±2g. All studies
involving mice were approved by the institute’s Animal
Care and Use Committee.
B16-luc
þ or H460-luc
þ tumor cells (1 10
6 or 1 10
7,
respectively) were injected subcutaneously into the dorsal
flanks of the BALB/c and nude mice and tumor growth
was monitored twice a week by in vivo imaging or external
caliper measurement. Mice bearing subcutaneous mela-
noma tumors and subcutaneous lung tumors were grown
about 7–10 days until the tumor size was approximately
200mm
3. A total of 5 10
5 B16 cells were injected into
nude mice through the tail vein and extensive lung
metastases occurred within 2 weeks after cellular im-
plantation.
Bioluminescence imaging
B16-F10 melanoma and H460 lung carcinoma xenografts
were established as above. Luminescent bacteria were
grown and harvested at late logarithmic phase, washed
and diluted with sterile normal saline and injected via the
tail vein into tumor-bearing or non-tumor-bearing mice at
various doses ranging from 1 10
6 to 1 10
10 c.f.u. per
mouse. To analyze bacterial luciferase activity and trace
bioluminescent bacteria, luminescence was quantified
from the in vivo signals emitted from the dorsal or ventral
views of each mouse prior to killing and from ex vivo
images taken of excised tissue immediately after being
killed. Total photon emission from different parts within
the images of each mouse was quantified at different time
points using the Living Image software (Xenogen).
For recording tumor growth by in vivo imaging, the
animals were injected intraperitoneally with D-luciferin at
150mgkg
 1 in Dulbecoo’s phosphate buffered saline and
anesthetized with 1–3% isoflurane. The mice were then
placed on a warmed stage inside a light-tight camera box
with continuous exposure to 1–3% isoflurane. Imaging
time ranged from 1s to 3min, depending on the tumor
model and time points. Low levels of light emitted from
the bioluminescent tumors were detected by an IVIS,
and were integrated, digitized and quantified as photons/
second using the Living Image software.
Cytotoxicity assay
H460 cells were seeded in 24-well plates at a density of
1 10
5 cells per well in 500ml of complete culture
medium. After 12–18h of adherence, the cells were
treated with E. coli DH5a (sTRAIL) and E. coli DH5a
(empty vector) at various multiplicities of infection
(MOIs) (50:1, 100:1, 200:1 and 400:1) in fresh culture
medium containing 5% penicillin and streptomycin to
inhibit bacterial growth. Cell morphology was observed
by light microscopy after 12h of incubation. For blocking
assay, H460 cells were incubated with 0 to 200ng of death
receptor4 (DR4):Fc or TNF receptor:Fc (both from
Alexis Biochemicals, San Diego, CA, USA) per milliliter
in addition to E. coli DH5a (sTRAIL) or E. coli DH5a
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and the results were documented as photographs. Unless
otherwise specified, E. coli DH5a (empty vector) was used
as vector control and the cell culture medium as mock
control.
Cells plated in 12-well dishes were infected with E. coli
DH5a (sTRAIL) at different MOIs and stained with
crystal violet. The medium was removed 12h after co-
incubation and the cells were fixed for 3min in 4%
paraformaldehyde at room temperature prior to crystal
violet staining. Fixed cells were washed with phosphate-
buffered saline and incubated for 3min in 1% crystal
violet in 70% ethanol. Cells were rinsed three times with
water, air-dried and photographed. Cells in a duplicate
plate were trypsinized and stained with trypan blue and
the percentage of viable cells was counted by light
microscopy.
Flow cytometry
H460 cells were infected with E. coli DH5a (sTRAIL) at
an MOI of 200 for 2, 4 or 8h. The cells were harvested by
trypsinization, followed by washing with cold phosphate-
buffered saline containing 10% fetal bovine serum and
fixation in 70% ethanol. The cells were then stained with
10mgml
 1 propidium iodide and analyzed using a
FACScan instrument.
Bacterial infection
In order to study bacterial infection on non-tumor
bearing or tumor-bearing mice in vivo, tissue samples
were obtained from liver, spleen and tumors after
injection as described above. Normal tissues and tumors
were excised, weighed and c.f.u. were determined at
different time points after homogenizing and plating
supernatants on LB agar plates.
For intratumoral (i.t.) injection, E. coli DH5a
(sTRAIL) induced by IPTG were harvested, washed and
diluted with sterile normal saline. Bacteria were injected
directly into the central area of the tumors at a dose of
1 10
9 c.f.u. per 50ml of sterile normal saline on the first
two successive days (total dose of 2 10
9 c.f.u.). For
intravenous injection, a total of 5 10
7 c.f.u. of E. coli
DH5a (sTRAIL) were injected into the tail vein of tumor-
bearing nude mice. One week later, the second injection
was performed as described as above. Unless otherwise
specified, E. coli DH5a (empty vector) was used as a
vector control, and sterile normal saline was used as a
mock control.
PCR assay and tissue immunohistochemistry
Established H460 tumors were allowed to grow until they
were approximately 200mm
3 in size. A total of 5 10
7
c.f.u. per mouse of E. coli DH5a (sTRAIL) was injected
i.v. through the tail vein into H460 tumor-bearing nude
mice. Four days after injection, animals were killed and
tumors, spleens, livers and kidneys were aseptically
removed, homogenized, diluted and plated onto LB agar
plates supplemented with 50mgml
 1 penicillin to deter-
mine the c.f.u. of E. coli DH5a (sTRAIL). Several
clones were randomly picked and PCR was performed
using the corresponding sTRAIL primers. At the same
time, normal tissues and tumors from nude mice were
fixed, paraffin-embedded and sectioned. Tissue immuno-
histochemistry were performed with an anti-hTRAIL
monoclonal antibody (clone 2H12) purchased from
R&D Systems (San Francisco, CA) using standard
methods.
Western blot analysis
H460 tumor cells were lysed in buffer (25mM Tris–Cl
(pH 7.4), 50mM NaCl, 0.5% Na-deoxycholate, 2%
Nonidet P-40, 0.2% SDS and 10% protease inhibitor
cocktail) and cell lysates were subjected to electrophoresis
on 15% SDS–PAGE gels and probed with rabbit anti-hDR4/
DR5 polyclonal antibody (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA).
Tumor size recording and animal survival rate
Mice were imaged along the dorsal view twice a week
from day 0 to day 20 after bacteria injection using an
IVIS. Bioluminescence was recorded as photons/second.
Tumor volume (mm
3) was measured by external calipers
twice weekly and calculated using the formula
L W
2 0.5, where L and W represent length and width
of the tumor in millimeters, respectively. All mice were
monitored for survival as previously described.
Pathological section and H&E staining
The tumors were removed from nude mice on day 3 after
bacteria injection. The tissue was fixed with 10% buffered
formalin and processed for paraffin sectioning and
hematoxylin–eosin (H&E) staining using standard meth-
ods.
Toxicity of sTRAIL in vivo
The toxicity of sTRAIL treatment delivered by E. coli
DH5a was examined following intravenous injection of
5 10
7 c.f.u. of E. coli DH5a (sTRAIL) to tumor-bearing
mice. Seven days later, a second injection was performed
as described above. At 4 and 30 days after infection,
serum from all mice was collected and aminotransferase/
aspartate aminotransferase was analyzed as indicator of
liver injury using standard method. Livers, spleens,
kidneys and hearts were harvested on day 30 after
bacteria injection and fixed in 10% buffered formalin.
The tissues were sectioned, stained with H&E and
histopathological changes in organs were examined.
Statistical analysis
The in vivo tumor growth data were analyzed by analysis
of variance using the Statistica software (StatSoft, Tulsa,
OK). The survival rates were analyzed by log-rank test
using Statistica. Pp0.05 was considered significant.
Results
E. coli DH5a specifically resides in tumors
A total of 1 10
8 c.f.u. of luminescent E. coli DH5a were
i.v. injected into tumor-bearing BALB/c or nude mice
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Cancer Gene Therapy(n410). Photon collection (3min) using the IVIS at 18h
after bacterial injection showed that detectable light
emission occurred only at the tumor site, indicating
presence of luminescent E. coli (Figure 1a). Luminescent
E. coli DH5a are also present in B16-F10 lung metastases
in nude mice (Figure 1a). We performed a dose escalation
test of E. coli DH5a and found that a dose of 1 10
8 or
5 10
7 c.f.u. in BALB/c mice or nude mice, respectively,
was optimal for observing bacterial distribution without
bacteremia. Unless otherwise specified, these doses were
used in all subsequent animal experiments.
To follow the fate of bacteria injected i.v. into the non-
tumor-bearing animals, we monitored each animal with
the IVIS at different time intervals as indicated in
Figure 1b (n410). Injection of E. coli DH5a immediately
resulted in light emission localized mainly in the lungs,
followed by accumulation of bioluminescent bacteria in
the liver, which was present for several hours. Imaging of
the same animals at 24h post-injection revealed that
detectable light emission from the earlier time points
diminished (Figure 1b). These findings, together with
complete absence of bacteria in the blood (data not
shown), indicate that the light-emitting bacteria were
probably eliminated by the host’s immune system.
Bacterial clearance was independently confirmed by
absence of light emission in all of the excised organs of
the same animal (data not shown).
To further determine the spatial and temporal progres-
sion of E. coli DH5a infection in animals with implanted
tumors, luminescent E. coli DH5a were i.v. injected into
BALB/c mice (n410) with melanoma (B200mm
3) that
had been growing in the right hind leg. The animals were
monitored each day for 15 days with a low-light imager.
Bioluminescence distribution patterns determined imme-
diately after injection were similar to distribution patterns
in non-tumor-bearing animals. However, at day 1 after
injection, no luminescence outside of the tumor region
was detected. Continued monitoring of the mice showed
that after an initial increase, luminescence decreased until
day 4, and then dramatically increased in the tumors
(Figure 1b), indicating efficient replication of the bacteria.
Furthermore, i.v. injected luminescent E. coli DH5a also
replicated in the human lung xenografts on nude mice
(n410; Figure 1b). At 30min and 4 days post-infection,
five of the tumor-bearing animals were killed. Lumine-
scence in the excised liver and lung tissue was detected at
the 30-min time point as indicated in Figure 1c. In
contrast, detectable light emission only existed within the
tumor site at day 4 post-infection, indicating that
distribution of E. coli DH5a into tumors via the blood-
stream did not result in significant infection of healthy
organs (Figure 1c). The results of the bacterial count
using homogenized samples at day 4 post-infection
indicate that E. coli DH5a preferentially accumulates in
tumors rather than in the spleens and livers at a ratio of
410000:1. The numbers of bacteria detected in tumors
was maintained as long as 18 days, while those in spleens
and livers gradually disappeared (Figure 1d).
Figure 1 E. coli DH5a specifically resides in tumors. (a) Bacteria in tumors can be detected as early as 18h after injection of 1 10
8 c.f.u. E. coli
DH5a through the tail vein (left, B16-F10 murine melanoma in BALB/c mice; middle, H460 human lung carcinoma in nude mice; right, B16-F10
murine lung metastases in nude mice). (b) Tissue distribution of E. coli DH5a in immunocompetent BALB/c mice and immunocompromised nude
mice using IVIS at different time points. Bars: photons/second (c) Various organs and tumors were removed from the mice and imaged using the
IVIS without any processing at 30min and day 4 after bacteria injection. (d) At different time points after infection, mice were killed. The livers,
spleens and tumors were excised, homogenized and assayed for bacterial titers. ND, not detectable. Each value represents mean±s.d. from
10 mice. Photon collection was for 3min at different time points after bacteria injection using the Xenogen IVIS 50 imaging system. C.f.u.,
colony-forming units; IVIS, In Vitro Imaging System.
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We then constructed a strain of sTRAIL-expressing
E. coli DH5a, which could specifically target sTRAIL
proteins into tumors. To determine whether sTRAIL-
expressing E. coli DH5a had cytotoxic effects on human
tumor cell lines in vitro, H460 lung tumor cells were
incubated with E. coli DH5a (empty vector) and sTRAIL-
expressing E. coli DH5a at various MOIs for 12h. The
cells were visualized by light microscopy for signs of
apoptosis. Cells incubated with E. coli DH5a (empty
vector) showed slight toxic effects, whereas cells incubated
with sTRAIL-expressing E. coli DH5a underwent rapid
and massive apoptosis (Figure 2a). A fusion protein
having DR4 extracellular domain fused to the immuno-
globulin Fc region (DR4: Fc) was added to the cell
cultures which reduced, in a concentration-dependent
manner, the amount of apoptotic cells and blocked
morphological changes associated with apoptosis. As a
negative control, 200ng of TNF receptor:Fc per ml,
which binds TNF but not TRAIL, was added to the cells
and failed to block DH5a (sTRAIL)-induced apoptosis
(Supplementary Figure S1).
Further analyses demonstrated that the sTRAIL
expressed by E. coli DH5a induces apoptosis in a dose-
dependent fashion (Figures 2b and c). Apoptosis was
characterized by FACS analysis in Figure 2d. The sub-G1
cell population increased in the E. coli DH5a (sTRAIL)-
treated group in a time-dependent manner. These results
indicate that E. coli DH5a-expressed sTRAIL effectively
induces tumor cells apoptosis.
Antitumor activity of sTRAIL-expressing E. coli DH5a
in vivo
These in vitro results encouraged us to evaluate whether
tumor apoptosis by sTRAIL-expressing E. coli DH5a
could be demonstrated in vivo. Nude mice (n¼20) with
luc
þ-labeled H460 lung tumors approximately 200mm
3
in size were intratumorally injected with E. coli DH5a
(empty vector) or E. coli DH5a (sTRAIL). Tumor growth
was monitored by two-dimensional caliper measurement
and by in vivo tumor imaging after intraperitoneal
injection of luciferin. As indicated in Figures 3a and b,
H460 tumors in the mock control group grew exponen-
tially, increasing 20-fold in size over the time period
examined. Tumor growth was significantly inhibited at 1
week post-injection both in the vector control and in the
E. coli DH5a (sTRAIL) groups, compared with that in
the mock control group (Po0.0001), and the difference
between the vector control and E. coli DH5a (sTRAIL)
groups was not significant (P¼0.29). In the vector
control group, all tumors underwent regrowth during
the subsequent 3 weeks, reaching a 17-fold increase as
compared with the original tumor size. These results
suggest that E. coli DH5a alone had little effect on the
Figure 2 Cytotoxicity of E. coli DH5a expressing sTRAIL in vitro. (a) H460 cells were infected with E. coli DH5a (sTRAIL) and E. coli DH5a
(empty vector) at various MOIs and the morphological features of each cell were analyzed with a phase-contrast inverted microscope. (b) Cells
were treated as described in panel a for 12h, fixed and stained with crystal violet and photographed. (c) Cell survival was determined by trypan
blue exclusion assay. The values represent the means of the values from triplicate wells. (d) The efficacy of sTRAIL-expressing E. coli DH5a on
H460 tumor cells in vitro by FACS analysis with an MOI of 200 for 2, 4 and 8h. The percentage of apoptotic cells was determined by quantifying
sub-G1 cells after treatment. The representative results of three independent experiments are shown. Mock Control: Cells treated with cells
culture medium; Vector Control: cells treated with E. coli DH5a (empty vector). FACS, fluorescence-activated cell sorting; MOI, multiplicity of
infection; sTRAIL, soluble TRAIL; TRAIL, tumor necrosis factor (TNF)-related apoptosis-inducing ligand.
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inhibition on day 30 post-injection. In the E. coli DH5a
(sTRAIL)-treated group, tumor growth was substantially
suppressed as compared with that in control mice. The
difference in tumor volume on day 30 between the
sTRAIL-treated group and the mock or vector control
groups is statistically significant (Po0.0001; Figure 3b).
We next examined whether in vivo delivery of sTRAIL
by E. coli DH5a into tumor tissues induces tumor cell
death via apoptosis. To address this question, we injected
the mock control, the E. coli DH5a vector control and
sTRAIL-expressing E. coli DH5a into established tumors,
excised the tumor tissues 3 days later and performed
histological analysis on tissue sections. As shown in
Figure 3c, H&E staining reveals that tumors injected with
sTRAIL-expressing E. coli DH5a showed much more
areas of necrosis and numerous cells with condensed
nuclei as compared with the control groups. These
data clearly indicate that sTRAIL-expressing E. coli
DH5a suppresses tumor growth by inducing tumor cell
apoptosis.
In general, local therapies such as i.t. injection have
limited efficacy in clinical treatments. Therefore, the
antitumor efficacy of sTRAIL-expressing E. coli DH5a
was tested following systemic delivery. As a result, tail-
vein injection of E. coli DH5a had little effect on tumor
regression. In contrast, tumor growth was significantly
retarded in mice treated with sTRAIL-expressing E. coli
DH5a. The mean tumor volumes in mice treated with
sTRAIL-expressing E. coli DH5a was dramatically lower
than that of tumors treated with sterile normal saline on
day 30 (Po0.0001). The difference between the sTRAIL-
treated group and the vector control group is also
statistically significant (P¼0.008; Figure 4a). Moreover,
survival of mice treated with sTRAIL-expressing E. coli
DH5a was significantly prolonged as compared with that
of mock- or vector control-treated mice. The survival of
mock- and vector control-treated animals was about 40%
at day 30 post-injection, whereas all the mice treated with
sTRAIL-expressing E. coli DH5a were still alive at the
same time point (Figure 4b).
Validation and toxicity
To further confirm that sTRAIL-expressing E. coli DH5a
localizes preferentially in tumors, we performed PCR on
bacterial colonies obtained from tumor tissues. H460
tumors were allowed to grow in nude mice until they were
approximately 200mm
3 in size, and then 5 10
7 c.f.u. of
sTRAIL-expressing E. coli DH5a were injected through
the tail vein. Four days after injection the animals were
killed and tumors, spleens, livers and kidneys were
aseptically removed, homogenized, diluted and plated
onto LB agar plates supplemented with 50mgml
 1
penicillin to determine the c.f.u. of sTRAIL-expressing
E. coli DH5a. As shown in Figure 5a, sTRAIL-expressing
E. coli DH5a was found preferentially within the tumor
tissue. PCR analysis using sTRAIL primers of randomly
picked bacterial colonies showed that the bacteria
cultured from the tumors contained the sTRAIL
plasmids. Immunohistochemical analysis of tumor tissues
Figure 3 The antitumor activity of sTRAIL-expressing E. coli DH5a when administered intratumorally. (a) Whole-body imaging of the efficacy of
sTRAIL-expressing E. coli DH5a on the growth of H460 tumors after i.t. injection. Tumors were imaged at the indicated time points after bacteria
injection. Bar: photons/second. (b) Tumor volume (mm
3) was also measured by external calipers twice per week and calculated as described
under Materials and methods. Each point represents the mean for n¼20 animals. The results represent the mean±s.d. The experiment was
repeated independently at least three times with similar results. The arrows indicate time points at which treatment was administered. (c) Necrotic
areas and more condensed nuclei were seen in H460 tumors on day 3 after injection with sTRAIL-expressing E. coli DH5a. Scale bars, 50mm.
sTRAIL, soluble TRAIL; TRAIL, tumor necrosis factor (TNF)-related apoptosis-inducing ligand.
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addition, sTRAIL protein was undetectable by a TRAIL-
specific ELISA in mice serum on day 1, 4 and 7 after
5 10
7 c.f.u. of DH5a (sTRAIL) were injected i.v. (data
not shown).
To determine whether E. coli DH5a (sTRAIL) caused
hepatocellular toxicity in vivo, we measured the serum
levels of two indicators of hepatocellular damage, alanine
aminotransferase and aspartate aminotransferase, at 4
and 30 days after infection. As shown in Figure 5c, the
values for serum aminotransferase and aspartate amino-
transferase were within normal ranges, and no significant
difference was found among the groups. Furthermore,
histological analysis of liver sections performed on day 30
showed that expression of sTRAIL did not cause
any pathological changes as compared with those in
Figure 5 Validation and toxicity. (a) Comparison of the numbers of sTRAIL-expressing E. coli DH5a in both tumor and normal tissues at 4 days
post-injection of viable bacteria into tumor-bearing mice through the tail vein. The experiments were repeated at least three times. Bacterial
clones from the tumor plate were determined by PCR assay using the corresponding sTRAIL primers. ‘—’ indicates negative control with E. coli
DH5a (empty vector) as PCR template. (b) Immunohistochemical staining for sTRAIL protein on different organs obtained from day 4 post-
injection of sTRAIL-expressing E. coli DH5a. Scale bars, 50mm. (c) Hepatotoxicity in tumor-bearing nude mice after systemic administration of E.
coli DH5a-expressed sTRAIL. Serum samples were collected 4 and 30 days after tail-vein injection and aminotransferase/aspartate
aminotransferase was measured using standard method. The values represent the mean±s.d. for 10 animals. (d) H&E-stained liver sections
from the same animals as in panel c on day 30 after tail vein-injection. Scale bars, 50mm. H&E, hematoxylin–eosin; sTRAIL, soluble TRAIL;
TRAIL, tumor necrosis factor (TNF)-related apoptosis-inducing ligand.
Figure 4 Efficacy of sTRAIL-expressing E. coli DH5a on tumor growth and animal survival in vivo when administered systematically. (a)
Quantitative efficacy of sTRAIL-expressing E. coli DH5a on the growth of H460 tumors in nude mice after intravenous injection. Tumor volume
(mm
3) was measured by external calipers twice per week and calculated as described under Materials and methods. Each point represents the
mean for n¼20 animals. The experiment was repeated independently at least three times with similar results. The arrows indicate time points at
which treatment was given. (b) Effect of sTRAIL-expressing E. coli DH5a on the survival of animals bearing subcutaneous H460 xenografts.
Animals (n¼20) were treated as described under Materials and methods. sTRAIL, soluble TRAIL; TRAIL, tumor necrosis factor (TNF)-related
apoptosis-inducing ligand.
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Cancer Gene Therapymock- and vector control-treated mice (Figure 5d).
Histological analysis of other tissues produced similar
results to those obtained from liver (data not shown).
Notably, mice injected with 5 10
7 c.f.u. of sTRAIL-
expressing E. coli DH5a once per week for two
consecutive weeks tolerated the infection and survived
longer than mock- and vector control-treated mice
(Figure 4b). We also examined the effect of DH5a
(sTRAIL) on the TRAIL sensitivity of tumor cells and
demonstrated that H460 cells aseptically separated from
the tumor-bearing mice treated with DH5a (sTRAIL) are
still susceptible to TRAIL-induced apoptosis (Supple-
mentary Figure S2a). Consistently, expression of TRAIL
receptor DR4/DR5 was not obviously affected by DH5a
or DH5a (sTRAIL) administration (Supplementary
Figure S2b). All these results suggest that E. coli DH5a-
mediated sTRAIL expression kills tumor cells without
detectable toxicity on normal cells.
Discussion
Specifically inducing tumor cells to undergo apoptosis is a
promising therapeutic approach for cancer. In this study,
we showed that non-pathogenic E. coli carrying a soluble
TRAIL protein administered systemically, selectively
localized in tumors and resulted in persistent tumor
growth inhibition in mice. This treatment combines the
advantages of tumor-targeting E. coli and the potent
antitumor effects of sTRAIL.
The sTRAIL protein in various forms has been
demonstrated to induce apoptosis of many cancer cells
in vitro and inhibit growth of many tumors in rodent
models. The sTRAIL protein acts by activating the
cell-surface DR4 and DR5.
35,36 In our study, inhibition
of tumor growth was mediated by sTRAIL protein
expressed in E. coli, since E. coli carrying the empty
vector did not have tumor inhibition activity and a
DR4:Fc fusion molecule could block the sTRAIL-
harboring E. coli from inducing H460 cell apoptosis
in vitro.
Bacteria, including S. typhimurium, have recently
gained attention as tumor-targeting vectors.
37,38 These
bacteria selectively localize in tumor tissues when
administered systemically, while the widely used adeno-
viral vector and adeno-associated virus vector do not have
inherent tumor tropism and their tumor specificity is
usually achieved via i.t. vector delivery.
39 Otherwise, side
effects associated with systemic administration of these
viral vectors and the transgene products expressed would
be a significant concern.
40 The tumor targeting in mice by
E. coli, as observed in this study, is impressively specific
and efficient. E. coli DH5a administered i.v. localized
specifically in several types of solid tumors in mice
(murine B16 melanoma in BALB/c mice, human H460
lung carcinoma in nude mice) and also in multiple tiny
metastatic sites of murine B16 melanoma in nude mice.
This specific tumor targeting is possibly a mechanism
related to the unique leaking tumor vasculature, the
immune-suppression environment or the rich nutrient
environment of tumor tissues.
41 The tumor-targeting
property of S. typhimurium has been confirmed in dogs
and humans in addition to mice, although with varied
efficiency.
27,42–44 Nevertheless, these findings offer cau-
tious optimism for using bacteria as tumor gene therapy
vectors.
Another prominent feature of bacterial gene delivery
vectors is that they are fully replication-competent while
adenovirus or adeno-associated virus gene delivery
vectors used for in vivo therapy purpose are usually
replication-incompetent. This feature provides a basis for
the in vivo persistence of the bacterial vectors and the
therapeutic gene they carry. In our experiments, E. coli
could be detected from the tumor tissue up to 1 month
after administration (data not shown). The recombinant
sTRAIL protein has a short half-life in vivo: from 3 to
5min in mouse and 30min in cynomolgus monkeys or
chimpanzees.
12 But the E. coli-expressed sTRAIL protein
could be detected in tumor tissue at 4 days after
administration. sTRAIL expression at later time points
had not been determined, but the flat tumor growth curve
at 3 weeks after the last administration suggests that
sTRAIL expression in tumor might have lasted much
longer. Moreover, E. coli DH5a delivery of sTRAIL
protein results in diffusion throughout tumor tissues
through the bloodstream. This may lead to increased
extensive tumor killing, transcending the limitations of
current gene therapies by affecting infected cells and
adjacent areas.
45
Compared with other bacterial vectors with potential
for tumor gene delivery, the E. coli vector employed here
has certain advantages. First, E. coli is an extracellular
bacterium while S. typhimurium is mainly intracellular.
Since the sTRAIL molecule acts by interacting with the
extracellular portion of its receptor, it would be advanta-
geous and more efficient to have sTRAIL released by an
extracellular bacterium. Secondly, as a facultative anae-
robic bacterium, E. coli can grow in both small and large
tumors, whereas anaerobic bacterium can only grow in
large tumors with a necrotic center.
Bacterial vectors administered systematically would
inevitably result in some complications, including certain
level of bacteremia and induction of circulating proin-
flammatory cytokines due to their endotoxin. In clinical
trials of the attenuated S. typhimurium strain VNP20009,
tumor localization was only found in some patients
receiving the bacteria at high doses where dose-limiting
toxicity was found.
27 E. coli will probably share some of
these complications. However, many E. coli species are
harbored by humans and other mammalian species in
their digestive tract in a symbiotic relationship; thus
non-pathogenic E. coli bacteria are likely to evoke a lower
immune response and toxicity response in animals as
compared with that by attenuated S. typhimurium. In this
study, the endotoxin levels in mice plasma on day 0.5, 1, 3
and 7 after intravenous injection of 5 10
7 c.f.u. DH5a
were found to differ non-significantly between the
bacteria-injected mice and normal saline-injected mice
(data not shown). Thus, in terms of safety profile and
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hold more potential than other bacteria. Furthermore,
E. coli are the most thoroughly studied and known
bacteria; numerous well-characterized strains and tools
are available for their manipulation, which will certainly
facilitate related studies.
To our knowledge, this is the first report of tumor
suppression in vivo achieved by using E. coli as the protein
delivery vector. This E. coli DH5a (sTRAIL) therapy
could serve as a prototype for further development of a
feasible and effective form of treatment for solid tumors.
In addition, our study has general implications for the
application of non-pathogenic E. coli as human gene
therapy vectors.
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